PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam…
Read the full articleYou might also wanna read
Prime wins patent fight with Beam to continue work on AATD gene editing therapy
Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ru
STAT+: Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
Aragen partners with Renaissance Pharma to manufacture rare disease therapy
The biotech firm produced its first commercial-scale GMP batches of lead-candidate Daretabart.
STAT+: Prime wins Beam arbitration, clearing path to clinic
AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The Readout
Navigating the Complex Landscape of Cell and Gene Therapy Manufacturing
Consultants from ProPharma express optimism about the trajectory of cell and gene therapy despite technical and logistical difficulties rema
Parham Habibzadeh: How the COMPETE Trial Could Reshape Treatment Sequencing for Progressive GEP-NETs
Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “Phase 3 COMPETE trial just published in the Lancet [¹⁷⁷Lu] Lu-ed
Comments
Sign in to join the conversation.
No comments yet. Be the first.